Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)
Richard Aspinall(Queen Alexandra Hospital), Debbie L. Shawcross(King's College - North Carolina), Mark Wright(University Hospital Southampton NHS Foundation Trust), Roland Henrar, Paul Richardson(University of Liverpool), Robert Przemioslo(Southmead Hospital), Melanie Kent(University Hospital of North Durham), Elizabeth Farrington(Royal Cornwall Hospital), Stephen Ryder(Nottingham University Hospitals NHS Trust), Joe Hickey, Mark Hudson(The Open University)
Cited by 5
Related Papers
Ancient genomes from northern China suggest links between subsistence changes and human migration
|Nature Communications|2020|342
Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine
|Journal of Hepatology|2000|205
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
|The Lancet HIV|2020|177
Severe hepatitis E infection during pregnancy
|Journal of Viral Hepatitis|1997|144